利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.035 秒)

    GP96 derived peptides
    2.
    发明授权
    GP96 derived peptides 有权
    GP96衍生肽

    公开(公告)号：US08512708B2

    公开(公告)日：2013-08-20

    申请号：US12921920

    申请日：2009-03-12

    申请人： Yossef Kliger ,  Ofer Levy ,  Itamar Borukhov ,  Anat Amir ,  Anat Oren

    发明人： Yossef Kliger ,  Ofer Levy ,  Itamar Borukhov ,  Anat Amir ,  Anat Oren

    IPC分类号： A61K39/00

    CPC分类号： C07K14/4703 ,  A61K38/00

    摘要： Provided is a gp96-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.

    摘要翻译： 提供了gp96衍生的肽或其同系物或衍生物，包含它们的药物组合物，其用于治疗和制备药物的用途，用于治疗广泛的病症，疾病和疾病的方法，编码它们的核苷酸序列 针对其表位的抗体和包括它们的融合蛋白。

    ELAPSED CYCLE TIMER IN LAST BRANCH RECORDS
    8.
    发明申请
    ELAPSED CYCLE TIMER IN LAST BRANCH RECORDS 有权
    最近分支记录中的ELAPSED循环定时器

    公开(公告)号：US20140380027A1

    公开(公告)日：2014-12-25

    申请号：US13922421

    申请日：2013-06-20

    申请人： Ahmad Yasin ,  Michael W. Chynoweth ,  Ofer Levy ,  Jason W. Brandt ,  Angela Schmid

    发明人： Ahmad Yasin ,  Michael W. Chynoweth ,  Ofer Levy ,  Jason W. Brandt ,  Angela Schmid

    IPC分类号： G06F9/30

    CPC分类号： G06F9/3806 ,  G06F9/30058 ,  G06F9/30098 ,  G06F11/3419 ,  G06F11/348 ,  G06F2201/865 ,  G06F2201/88

    摘要： A processing device implementing an elapsed cycle timer in last branch records (LBRs) is disclosed. A processing device of the disclosure includes a last branch record (LBR) counter to iterate with each cycle of the processing device and an LBR structure communicably coupled to the LBR counter. The LBR structure comprises a plurality of LBR entries. Furthermore, an LBR entry of the plurality of LBR entries comprises an address instruction pointer (IP) of a branch instruction executed by the processing device, an address IP of a target of the branch instruction, and an elapsed time field that stores a value of the LBR counter when the LBR entry is created.

    摘要翻译： 公开了一种在最后的分支记录（LBR）中实现经过周期定时器的处理装置。 本公开的处理装置包括与处理装置的每个周期重复的最后一个分支记录（LBR）计数器和可通信地耦合到LBR计数器的LBR结构。 LBR结构包括多个LBR条目。 此外，多个LBR条目的LBR条目包括由处理装置执行的分支指令的地址指令指针（IP），分支指令的目标的地址IP以及存储分支指令的值的经过时间字段 当创建LBR条目时，LBR计数器。

    RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE
    10.
    发明申请
    RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE 审中-公开
    RANTES水平作为诊断和治疗急性冠状动脉疾病

    公开(公告)号：US20120238460A1

    公开(公告)日：2012-09-20

    申请号：US12739976

    申请日：2008-11-10

    申请人： Ofer Levy ,  Eva Guinan ,  Eugenie Suter

    发明人： Ofer Levy ,  Eva Guinan ,  Eugenie Suter

    IPC分类号： C40B30/04

    CPC分类号： G01N33/6863 ,  G01N2333/523 ,  G01N2800/245 ,  G01N2800/50

    摘要： Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level.

    摘要翻译： 本文公开了用于确定受试者在接受清髓性同种异体造血干细胞移植（HSCT）时发展为急性移植物抗宿主病（aGVHD）的可能性的方法。 一种这样的方法包括测定从受试者获得的样品中RANTES的基线血浆浓度，并将RANTES的基线血浆浓度与预定水平进行比较。 该方法还可以包括测定从受试者获得的样品中RANTES的第7天血浆浓度，并将RANTES的第7天血浆浓度与预定水平进行比较。 另一种这样的方法包括测定从受试者获得的样品中RANTES的第7天血浆浓度，并将RANTES的第7天血浆浓度与预定水平进行比较。 另一种这样的方法包括测定从造血干细胞的供体获得的样品中RANTES的供体血浆浓度，并将RANTES的供体血浆浓度与预定水平进行比较，其中RANTES的供体血浆浓度小于预定水平表明 接受来自该供体的清髓性同种异体HSCT的受试者可能发生GV​​HD。 其他方法包括测定从受试者获得的样品中的第0天或第7天MCP-1的血浆浓度，并将MCP-1的血浆浓度与第0天或第7天的血浆浓度进行比较。